Sana Biotechnology
SANA
80 hedge funds and large institutions have $1.93B invested in Sana Biotechnology in 2021 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 33 increasing their positions, 12 reducing their positions, and 17 closing their positions.
131,700% more call options, than puts
Call options by funds: $1.32M | Put options by funds: $1K
175% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 12
12% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 17
3.04% more ownership
Funds ownership: 49.34% → 52.38% (+3%)
3% more funds holding
Funds holding: 78 → 80 (+2)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
38% less capital invested
Capital invested by funds: $3.1B → $1.93B (-$1.16B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Crestline Management
Fort Worth,
Texas
|
+$72.8M |
| 2 |
State Street
Boston,
Massachusetts
|
+$40M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$28.4M |
| 4 |
Public Sector Pension Investment Board (PSP Investments)
Montreal,
Quebec, Canada
|
+$8.54M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$6.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
-$12.9M |
| 2 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$12.2M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
-$8.15M |
| 4 |
EC
EMJ Capital
Toronto,
Ontario, Canada
|
-$6.69M |
| 5 |
JP Morgan Chase
New York
|
-$6.11M |
SANA Hedge Fund Activity: Q2 2021 in Review
80 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Sana Biotechnology (SANA) for Q2 2021, worth a combined $1.93B — down 38% from $3.1B a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new SANA positions and 17 closed out — a net gain of 2 holders — while 33 added to existing stakes and 12 trimmed.
The largest buyer was Crestline Management, opening a new position worth an estimated $72.8M. The largest seller was Suvretta Capital Management, cutting an estimated $12.9M.
- 80 institutional investors held Sana Biotechnology (SANA) as of Q2 2021, up from 78 in Q1 2021.
- Funds reported $1.93B of Sana Biotechnology stock for Q2 2021, down 38% quarter-over-quarter.
- 19 funds opened new Sana Biotechnology positions in Q2 2021 and 17 closed out, a net change of +2 holders.
- The largest Sana Biotechnology buyer in Q2 2021 was Crestline Management, an estimated $72.8M added.
- The largest Sana Biotechnology seller in Q2 2021 was Suvretta Capital Management, an estimated $12.9M sold.
Based on aggregated 13F filings for Q2 2021.